Business Wire

NY-MOODY'S/METLIFE

Share
Moody’s Teams Up with the New York Giants and New York Jets as the New Cornerstone Partner of MetLife Stadium

Moody’s Corporation, the world’s leading source of bold, clear and perceptive insights on exponential risk, announced today that it has been named an Official Cornerstone Partner of MetLife Stadium, home of the New York Jets and New York Giants.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423976836/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

As part of the multi-year partnership, Moody’s branding will be a mainstay at MetLife Stadium events, extending throughout the stadium with in-bowl signage and digital displays. Guests will first be greeted at the Moody’s Gate (pictured above) and then pass through an activation area on the plaza. Moody’s is also the naming rights partner of the Moody’s Commissioners Club, a spectacular private space in the Stadium offering guests unparalleled views and unique experiences at events.

“In trying to find organizations that align with Moody’s renewed brand of decoding complexity and finding a path forward in the face of risk or adversity, we couldn’t think of better partners than MetLife Stadium and the New York Giants and New York Jets,” said Christine Elliott, Chief Corporate Affairs Officer of Moody’s. “These institutions continually demonstrate what it takes to triumph over adversity, show us how to address complexity through teamwork and collaboration, and inspire and entertain us with each and every play. We are honored to join together with these venerable partners as the new season begins to unfold, starting this Thursday with the NFL Draft.”

“We are honored that Moody’s has chosen MetLife Stadium to showcase its new brand platform,” said Ron VanDeVeen, President and CEO of MetLife Stadium. “Having a reputable, New York-based company like Moody’s fits in perfectly with our gameday environment.”

“MetLife Stadium has been the center of entertainment since it opened in 2010,” said Hymie Elhai, President of the New York Jets. “Welcoming a new cornerstone partner like Moody’s will elevate our fan experience from the moment they enter the stadium at the Moody’s Gate and will provide an enhanced experience for our Moody’s Commissioners Club guests. We are excited to kickoff this partnership and work together on ways to reinforce our commitment to our fans.”

“Moody’s exemplifies everything we look for in a Cornerstone partner and we are thrilled to welcome them to MetLife Stadium,” said John Mara, New York Giants President and CEO. “We look forward to developing our new partnership and engaging fans across stadium events and throughout our shared hometown.”

The partnership is part of Moody’s new global branding campaign, defining Moody’s as a category of one. In a world shaped by increasingly interconnected risks, it is more difficult than ever for leaders to act with certainty. Organizations, companies, and governments need to go beyond data into context, and to go beyond context into meaning. That’s where Moody’s is in a category by itself. Through its vast data estate and unparalleled insights and analytics, Moody’s provides a compass for understanding complexity, helping customers decode risk, unlock opportunity, and inform a clear path forward in an era of exponential risk.

The financial terms of the partnership were not disclosed.

For more information, visit www.moodys.com.

About Moody’s Corporation
In a world shaped by increasingly interconnected risks, Moody’s (NYSE: MCO) data, insights, and innovative technologies help customers develop a holistic view of their world and unlock opportunities. With a rich history of experience in global markets and a diverse workforce of 15,000 across more than 40 countries, Moody’s gives customers the comprehensive perspective needed to act with confidence and thrive. Learn more at www.moodys.com.

About MetLife Stadium
MetLife Stadium, located in East Rutherford, NJ, is the home of the New York Jets and New York Giants and is one of the largest stadiums in the NFL (82,500). The stadium hosts the world’s biggest events on the world’s biggest stage and will host the FIFA World Cup 26™ Final and 7 other matches throughout the tournament. The venue annually ranks as one of the busiest stadiums in the world and has been named “Highest Grossing Stadium of the Year” 9 times by Billboard. Event highlights include Super Bowl XLVIII, NHL Stadium Series, WrestleMania, Copa America Centenario Final, 2021 Army-Navy Game, and many concerts, college football games, and international soccer matches.

About the New York Giants
A cornerstone franchise of the National Football League, the New York Football Giants began play in 1925. The Giants have won eight championships: 1927, 1934, 1938, 1956, 1986, 1990, 2007 and 2011. After twice winning two titles in five years, the Giants are the only NFL franchise with Super Bowl victories in four consecutive decades. Headquartered at the Quest Diagnostics Training Center in East Rutherford, N.J., the Giants enter their 100th season of play this fall.

About the New York Jets
The New York Jets were founded in 1959 as the New York Titans, an original member of the American Football League (AFL). The Jets won Super Bowl III, defeating the NFL’s Baltimore Colts in 1969. In 1970, the franchise joined the National Football League in the historic AFL–NFL merger that set the foundation for today’s league. As part of a commitment to its fan base through innovation and experiences, the team has created initiatives such as, its trailblazing Jets Rewards program, a state-of-the-art mobile app, and 1JD Entertainment, a comprehensive content platform that gives fans greater access to the team across all digital and social platforms. The organization takes great pride in a long-standing, year-round commitment to their community. These programs are funded by the New York Jets Foundation and look to positively influence the lives of young men and women in the tri-state area, particularly in disadvantaged communities. The organization supports the efforts of the Lupus Research Alliance, youth football and numerous established charitable organizations and causes sponsored by the NFL. The New York Jets play in MetLife Stadium, which opened in 2010, and are headquartered at the Atlantic Health Jets Training Center in Florham Park, New Jersey. For more information about the New York Jets visit newyorkjets.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240423976836/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye